Semax: Clinical Guide for Prescribing Practices
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone) fragments 4-10. Developed at the Institute of Molecular Genetics in Russia, it has been studied for neuroprotective and cognitive-enhancing properties. It is approved in Russia for stroke recovery and cognitive disorders.
Also Known As
How Semax Works
Semax activates the melanocortin system via MC3 and MC4 receptors and stimulates strong upregulation of BDNF and its receptor TrkB in the hippocampus and prefrontal cortex [1]. It enhances NGF (nerve growth factor) expression and modulates serotonin and dopamine metabolism, contributing to improved synaptic plasticity and neuroprotection [3]. The peptide also inhibits nitric oxide synthase in ischemic brain tissue, reducing excitotoxic damage during cerebrovascular events [4].
Clinical Evidence
Russian Phase III clinical trials demonstrated Semax's efficacy in accelerating neurological recovery after ischemic stroke when administered within 6 hours of onset [2]. Ashmarin et al. published studies showing significant improvements in attention, memory, and cognitive processing speed in patients with cognitive impairment [3]. Dolotov et al. confirmed BDNF upregulation of 1.5 to 3-fold in the hippocampus following intranasal administration [1]. Semax is approved in Russia for stroke recovery, cognitive disorders, and optic nerve atrophy based on accumulated clinical evidence [2].
Clinical Uses
Patient Selection and Screening
Best suited for patients with documented cognitive decline, post-stroke neurological recovery needs [2], or neurodegenerative conditions seeking neuroprotective interventions [4]. Appropriate for patients with attention deficits, brain fog, or age-related cognitive changes unresponsive to lifestyle interventions. Contraindicated in patients with active psychosis, severe hypertension, or endocrine tumors. Monitor adrenal function given the ACTH-derived structure, though Semax does not demonstrate glucocorticoid-stimulating activity at therapeutic doses [3].
Dosing and Administration
Standard intranasal dosing ranges from 200 to 600 mcg per administration, one to three times daily [1]. Treatment courses typically last 10 to 14 days for cognitive indications and up to 30 days for stroke recovery protocols [2]. Higher-potency N-Acetyl Semax (NASA) and N-Acetyl Semax Amidate (NASA Amidate) formulations allow lower volume dosing with potentially enhanced bioavailability. Cycling of 2 weeks on, 1 week off is common for cognitive enhancement applications. Administration should occur in the morning and early afternoon to avoid potential sleep interference.
Route: Intranasal
Protocol notes: Typically administered intranasally. Dosing varies by clinical indication and formulation.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Semax addresses the expanding cognitive optimization market, appealing to executives, aging professionals, and patients recovering from neurological events. Its intranasal delivery and non-controlled substance status simplify prescribing logistics. Practices can offer tiered cognitive enhancement protocols combining Semax with Selank and other nootropics, generating premium service revenue in a market with high patient willingness to pay out-of-pocket.
FDA Category Status
Expected to return to Category 1 per February 2026 HHS announcement
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Semax through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the difference between Semax and Selank?
References
- Dolotov OV et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates BDNF and trkB signaling in the rat hippocampus. Brain Res. 2006;1117(1):54-60.
- Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40.
- Ashmarin IP et al. The mechanisms of regulatory peptides action: the role of degradation products. Neurosci Res Commun. 1996;18(1):37-43.
- Eremin KO et al. Semax, an ACTH(4-10) analogue, regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics. 2002;271:583-93.
Related Peptides in Cognitive & Neurological
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Semax Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Semax Through Karpa